Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Liatermin (r-metHuGDNF)
Liatermin · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Liatermin | EXPERIMENTAL | Bilateral continuous infusion of liatermin for up to 24 months. |
| Name | Type | Description |
|---|---|---|
| Liatermin | BIOLOGICAL | Liatermin |
| Liatermin (r-metHuGDNF) | DRUG | - |
Inclusion Criteria: - Completion of the 20020168 protocol
Liatermin is an investigational therapy that was studied for idiopathic Parkinson's disease. It was delivered by bilateral intraputaminal infusion directly into the brain in a Phase 1 clinical trial. It is not an approved treatment and remains in clinical development.
Liatermin targets GFRA1, also known as the GDNF family receptor alpha-1. It acts as an agonist at this receptor, meaning it activates GFRA1 signaling. This receptor is part of the glial cell line-derived neurotrophic factor pathway, which is relevant to the survival of dopaminergic neurons affected in Parkinson's disease.
Liatermin is being developed by Amgen Inc., which trades on Nasdaq under the ticker AMGN. Amgen sponsored the Phase 1 clinical trials of Liatermin in idiopathic Parkinson's disease.
Liatermin is in Phase 1 clinical development. It has not been approved by the FDA for any indication. The completed Phase 1 trials enrolled a total of 34 participants with idiopathic Parkinson's disease, and no trials are currently active.
Liatermin has been studied in two completed Phase 1 trials: NCT00115427, which evaluated bilateral intraputaminal infusion in idiopathic Parkinson's disease, and NCT00111982, an extended treatment trial in participants who completed a prior Liatermin trial. Both trials are completed and enrolled adults aged 35 years and older.
Yes. Liatermin is also known as r-metHuGDNF, which stands for recombinant methionyl human glial cell line-derived neurotrophic factor. Both names refer to the same investigational agent developed by Amgen for Parkinson's disease.